SCHEMBL5355369

SCHEMBL5355369

CC(c1ccccc1)N1CN(C(C)c2ccccc2)CN(C(C)c2ccccc2)C1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 6/20 0.74
MC4R P32245 1/20 0.63
OPRM1 P35372 2/20 0.52
OPRD1 P41143 1/20 0.52
OPRK1 P41145 1/20 0.52
OPRL1 P41146 1/20 0.52
ALDH1A1 P00352 4/20 0.46
KCNH2 Q12809 5/20 0.43
CHRM2 P08172 4/20 0.43
CHRM1 P11229 4/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
ADRA2A P08913 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
CHRM3 P20309 1/20 0.43
DRD1 P21728 1/20 0.43
ADRA1D P25100 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HRH1 P35367 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6396631 0.95 CYP2D6 (0.68) CYP2D6MC4ROPRM1OPRD1OPRK1
SCHEMBL16306975 0.91 CYP2D6 (0.83) CYP2D6MC4ROPRM1OPRD1OPRK1
SCHEMBL20034046 0.91 CYP2D6 (0.83) CYP2D6MC4ROPRM1OPRD1OPRK1
SCHEMBL6706135 0.85 CYP2D6 (1.00) CYP2D6MC4ROPRM1OPRD1OPRK1
SCHEMBL16226061 0.85 CYP2D6 (1.00) CYP2D6MC4ROPRM1OPRD1OPRK1
SCHEMBL7264542 0.85 CYP2D6 (1.00) CYP2D6MC4ROPRM1OPRD1OPRK1
SCHEMBL14217972 0.83 CYP2D6 (0.53) CYP2D6MC4ROPRM1OPRD1OPRK1
SCHEMBL23850144 0.81 CYP2D6 (0.83) CYP2D6MC4ROPRM1OPRD1OPRK1
SCHEMBL3914022 0.81 CYP2D6 (0.68) CYP2D6MC4ROPRM1OPRD1OPRK1
SCHEMBL2792997 0.81 CYP2D6 (0.68) CYP2D6MC4ROPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7214842-B2 Method for oligomerizing olefins BASF AKTIENGESELLSCHAFT (DE) 2007-05-08 US disclosed
US-20050165266-A1 olefin is brought into contact with a catalyst system comprising at least one transition metal complex with a polydentate complexing ligand and an alkylaluminoxane; transition metal complex is added continuously or in portions during the oligomerization. BASF AKTIENGESELLSCHAFT (DE) 2005-07-28 US disclosed
EP-1497244-A1 METHOD FOR OLIGOMERIZING OLEFINS BASF AKTIENGESELLSCHAFT (DE) 2005-01-19 EP disclosed
US-6844290-B1 Oligomerization catalyst BASF AKTIENGESELLSCHAFT (DE) 2005-01-18 US disclosed
EP-1171445-B1 OLIGOMERISATION CATALYST BASF AG (DE) 2004-01-21 EP disclosed
WO-2003084902-A1 METHOD FOR OLIGOMERIZING OLEFINS BASF AKTIENGESELLSCHAFT (DE) 2003-10-16 WO disclosed
EP-1171445-A1 OLIGOMERISATION CATALYST BASF AKTIENGESELLSCHAFT (DE) 2002-01-16 EP disclosed
WO-2000058319-A1 OLIGOMERISATION CATALYST BASF AKTIENGESELLSCHAFT (DE) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165266-A1 olefin is brought into contact with a catalyst system comprising at least one transition metal complex with a polydentate complexing ligand and an alkylaluminoxane; transition metal complex is added continuously or in portions during the oligomerization. ALOX12, ALOX15B, ALOX15 CYP2D6 1688/4885MC4R 2269/4885OPRM1 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.